Philogen S.p.A. (BST:78Q)

Market Cap	818.37M -14.6%
Revenue (ttm)	315.27M +274.1%
Net Income	224.98M +390.0%
EPS	5.57 +387.1%
Shares Out	n/a
PE Ratio	3.65
Forward PE	106.46
Dividend	0.70 (3.51%)
Ex-Dividend Date	May 18, 2026

Volume	5
Open	20.30
Previous Close	20.30
Day's Range	19.90 - 20.40
52-Week Range	18.86 - 25.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Philogen

Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 230
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: 78Q

Financial Performance

In 2025, Philogen's revenue was 319.73 million, an increase of 313.81% compared to the previous year's 77.26 million. Earnings were 229.68 million, an increase of 407.10%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 30, 2026

Data Sources Report a data error